Ethic Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Ethic Inc.

$3.97 Billion
Q3 2024

A detailed history of Ethic Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ethic Inc. holds 3,976 shares of ALNY stock, worth $1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

3,976

Previous 3,527 12.73%

Holding current value

$1 Million

Previous $857,000 27.54%

% of portfolio

0.03%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $104,980 - $128,867	449 Added 12.73%	3,976 $1.09 Million
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $64,346 - $110,903	-449 Reduced 11.29%	3,527 $857,000
Q1 2024 May 13, 2024	SELL	$146.51 - $198.2 $4,834 - $6,540	-33 Reduced 0.82%	3,976 $594,000
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $51,025 - $66,244	337 Added 9.18%	4,009 $767,000
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $290,138 - $359,593	1,699 Added 86.11%	3,672 $650,000
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $84,179 - $96,482	455 Added 29.97%	1,973 $374,000
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $71,420 - $92,092	-391 Reduced 20.48%	1,518 $304,000
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $40,260 - $52,364	217 Added 12.83%	1,909 $453,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $23,828 - $39,904	172 Added 11.32%	1,692 $339,000
Q2 2022 Aug 10, 2022	BUY	$120.42 - $169.29 $183,038 - $257,320	1,520 New	1,520 $222,000
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $179,026 - $234,823	-1,122 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $190,459 - $233,073	1,122 New	1,122 $212,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ethic Inc. with notifications on news.

Account